Although the incretin effects of GIPR undoubtedly play a crucial role in preventing postprandial glucose excursion, there is still intensive debate on whether the GIPR should be activated or inhibited for the treatment of obesity. The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.